The University of Wisconsin Breast Cancer Epidemiology Simulation Model: An Update

Medical Decision Making

Volumn 38, Issue 1_suppl, 2018, Pages 99S-111S

  Alagoz, Oguzhan ^a   Ergun, Mehmet Ali ^a   Cevik, Mucahit ^b   Sprague, Brian L ^c   Fryback, Dennis G ^d   Gangnon, Ronald E ^d   Hampton, John M ^e   Stout, Natasha K ^f   Trentham Dietz, Amy ^e  

^a University of Wisconsin Madison   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^e UNIVERSITY OF WISCONSIN   (United States)

^f HARVARD MEDICAL SCHOOL   (United States)

Author keywords

breast cancer; incidence; screening; simulation

Indexed keywords

ADULT; AGED; BIOLOGICAL MODEL; BREAST TUMOR; CANCER REGISTRY; CANCER STAGING; COMPUTER SIMULATION; DIAGNOSTIC IMAGING; FEMALE; HUMAN; MAMMOGRAPHY; MIDDLE AGED; PATHOLOGY; PROCEDURES; REPRODUCIBILITY; RISK ASSESSMENT; RISK FACTOR; STATISTICAL MODEL; UNITED STATES; UNIVERSITY; VERY ELDERLY; WISCONSIN;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; COMPUTER SIMULATION; FEMALE; HUMANS; MAMMOGRAPHY; MIDDLE AGED; MODELS, BIOLOGICAL; MODELS, STATISTICAL; NEOPLASM STAGING; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; RISK FACTORS; SEER PROGRAM; UNITED STATES; UNIVERSITIES; WISCONSIN;

EID: 85040567016     PISSN: 0272989X     EISSN: 1552681X     Source Type: Journal    
DOI: 10.1177/0272989X17711927     Document Type: Article

References (44)

1. Berry DA, Cronin KA, Plevritis SK, Fryback DG, Clarke L, Zelen M. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med. 2005;353:1784–92.
2. Fryback DG, Stout NK, Rosenberg MA, Trentham-Dietz A, Kuruchittham V, Remington PL. The Wisconsin breast cancer epidemiology simulation model. J Natl Cancer Inst Monogr. 2006;36:37.
3. Cancer Intervention and Surveillance Modeling Network (CISNET). Breast Cancer Model Profiles; 2016. https://cisnet.cancer.gov/breast/profiles.html
4. Kelton WD, Law AM. Simulation Modeling and Analysis. Boston: McGraw Hill; 2000.
5. Holford TR, Cronin KA, Mariotto AB, Feuer EJ. Changing patterns in breast cancer incidence trends. J Natl Cancer Inst Monogr. 2005:19–25.
6. Gangnon RE, Sprague BL, Stout NK. The Contribution of Mammography Screening to Breast Cancer Incidence Trends in the United States: An Updated Age-period-cohort Model. Cancer Epidemiol Biomarkers Prev. 2015:24:905–12.
7. Shwartz M. Validation and use of a mathematical model to estimate the benefits of screening younger women for breast cancer. Cancer Detect Prev. 1980;4:595–601.
8. Spratt JS, Spratt JA. Growth rates. Cancer of the Breast. 2002; 5:443-76.
9. Segnan N, Minozzi S, Armaroli P, Cinquini M, Bellisario C, González-Lorenzo M. Epidemiologic evidence of slow growing, nonprogressive or regressive breast cancer: A systematic review. Int J Cancer. 2016;139:554–73.
10. Harris JR, Lippman ME, Veronesi U, Willett W. Breast cancer (2). N Engl J Med. 1992;327:390–8.
11. Harris J, Lippman M, Veronesi U, Willett W. Breast cancer. N Engl J Med. 1992;327:319–28.
12. Harris JR, Lippman ME, Veronesi U, Willett W. Breast cancer (3). N Engl J Med. 1992;327:473–80.
13. Zahl P-H, Andersen JM, Mæhlen J. Spontaneous regression of cancerous tumors detected by mammography screening. JAMA. 2004;292:2579–80.
14. Mandelblatt JS, Near AM, Miglioretti DL, Munoz D, Sprague BL, Trentham-Dietz A. Common model inputs used in CISNET collaborative breast cancer modeling. Med Decis Making. 2018;38(1S):9–23.
15. Wang YC, Graubard BI, Rosenberg MA, Kuntz KM, Zauber AG, Kahle L. Derivation of background mortality by smoking and obesity in cancer simulation models. Med Decis Making. 2013; 33(2):176-97.
16. Gangnon RE, Stout NK, Alagoz O, Hampton J, Sprague BL, Trentham-Dietz A. Contribution of breast cancer to overall mortality for US women. Med Decis Making. 2018;38(1S):24-31.
17. Tosteson AN, Stout NK, Fryback DG, Acharyya S, Herman BA, Hannah LG. Cost-effectiveness of digital mammography breast cancer screening. Ann Intern Med. 2008;148:1–10.
18. Stout NK, Rosenberg MA, Trentham-Dietz A, Smith MA, Robinson SM, Fryback DG. Retrospective cost-effectiveness analysis of screening mammography. J Natl Cancer Inst. 2006;98:774–82.
19. Lee CI, Cevik M, Alagoz O. Comparative effectiveness of combined digital mammography and tomosynthesis screening for women with dense breasts. Radiology. 2015;274:772–80.
20. Stout NK, Lee SJ, Schechter CB. Benefits, harms, and costs for breast cancer screening after US implementation of digital mammography. J Natl Cancer Inst. 2014;106:dju092.
21. Sprague BL, Stout NK, Schechter C. Benefits, harms, and cost-effectiveness of supplemental ultrasonography screening for women with dense breasts. Ann Intern Med. 2015;162:157–66.
22. Nelson HD, Zakher B, Cantor A. Risk factors for breast cancer for women aged 40 to 49 years: a systematic review and meta-analysis. Ann Intern Med. 2012;156:635–48.
23. Carney PA, Miglioretti DL, Yankaskas BC. Individual and combined effects of age, breast density, and hormone replacement therapy use on the accuracy of screening mammography. Ann Intern Med. 2003;138:168–75.
24. Batina NG, Trentham-Dietz A, Gangnon RE. Variation in tumor natural history contributes to racial disparities in breast cancer stage at diagnosis. Breast Cancer Res Treat. 2013;138:519–28.
25. Centers for Disease Control and Prevention. National Health and Nutrition Examination Survey. 2016; Available from: URL: http://www.cdc.gov/nchs/nhanes/.
26. Trentham-Dietz A, Sprague BL, Hampton JM. Modification of breast cancer risk according to age and menopausal status: a combined analysis of five population-based case-control studies. Breast Cancer Res Treat. 2014;145:165-75.
27. Shiyanbola OO, Arao RF, Miglioretti DL. Emerging trends in family history of breast cancer and associated risk. Cancer Epidemiology Biomarkers Prevention 2017;26(3):438-439.
28. Centers for Disease Control and Prevention. National Health Interview Survey. 2016; Available from: URL: http://www.cdc.gov/nchs/nhis/.
29. American College of Radiology BI-RADS Committee. ACR BI-RADS Atlas: Breast Imaging Reporting and Data System; 2013.
30. Breast Cancer Surveillance Consortium. Breast Cancer Surveillance Consortium. 2016; Available from: URL: http://www.bcsc-research.org/.
31. Sprague BL, Gangnon RE, Burt V. Prevalence of mammographically dense breasts in the United States. J Natl Cancer Inst. 2014;106:dju255.
32. Jewett PI, Gangnon RE, Trentham-Dietz A, Sprague BL. Trends of postmenopausal estrogen plus progestin prevalence in the United States between 1970 and 2010. Obstet Gynecol. 2014;124:727–33.
33. Sprague BL, Trentham-Dietz A, Cronin KA. A sustained decline in postmenopausal hormone use: results from the National Health and Nutrition Examination Survey, 1999–2010. Obstet Gynecol. 2012;120:595.
34. Munsell MF, Sprague BL, Berry DA, Chisholm G, Trentham-Dietz A. Body mass index and breast cancer risk according to postmenopausal estrogen-progestin use and hormone receptor status. Epidemiol Rev. 2014;36:114-36.
35. Centers for Disease Control and Prevention. Behavioral Risk Factor Surveillance System; 2016. Available from: URL: http://www.cdc.gov/brfss/.
36. Cronin KA, Miglioretti DL, Krapcho M. Bias associated with self-report of prior screening mammography. Cancer Epidemiol Biomarkers Prev. 2009;18:1699–705.
37. Cevik M, Ergun MA, Stout NK, Trentham-Dietz A, Craven M, Alagoz O. Using Active Learning for Speeding up Calibration in Simulation Models. Med Decis Making. 2016;36:581–93.
38. Alagoz O, Berry D, Feuer EJ, de Koning H, Lee SJ, Plevritis S. Introduction to the cancer intervention and surveillance modeling network (CISNET) breast cancer models. Medical Decision Making. 2018;38(1S):3–8.
39. van den Broek JJ, van Ravesteyn NT, Cevik M, Schechter CB, Lee SJ, Munoz D. Comparing CISNET breast cancer models using the maximum clinical incidence reduction methodology. Med Decis Making. 2018;38(1S):112–125.
40. van Ravesteyn NT, van den, Broek JJ, Li X, Weedon-Fekjar H, Schechter CB, Alagoz O. Modeling ductal carcinoma in situ (DCIS): An overview of CISNET model approaches. Med Decis Making. 2018;38(1S):126–139.
41. Munoz D, Near AM, van Ravesteyn NT. Effects of screening and systemic adjuvant therapy on ER-specific US breast cancer mortality. JNCI: Journal of the National Cancer Institute. 2014;106(11):dju289.
42. Mandelblatt JS, Cronin K, de Koning H, Miglioretti DL, Schechter C, Stout NK. Modeling Report: Collaborative Modeling of U.S. Breast Cancer Screening Strategies: Breast Cancer: Screening. U.S. Preventive Services Task Force. USPSTF; 2015 [cited September 12, 2015]; Available from: http://www.uspreventiveservicestaskforce.org/Page/Document/modeling-report-collaborative-modeling-of-us-breast-cancer-1/breast-cancer-screening1.
43. Moss SM, Cuckle H, Evans A, Johns L, Waller M, Bobrow L. Effect of mammographic screening from age 40 years on breast cancer mortality at 10 years’ follow-up: a randomised controlled trial. Lancet. 2006;368:2053–60.
44. Moss SM, Wale C, Smith R, Evans A, Cuckle H, Duffy SW. Effect of mammographic screening from age 40 years on breast cancer mortality in the UK Age trial at 17 years’ follow-up: a randomised controlled trial. Lancet Oncol. 2015;16:1123–32.